This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:



Primary hepatic angiosarcoma: Treatment options for a rare tumor

Credit: Pixabay/CC0 Public Domain

In an editorial, researchers Gregory L. Guzik and Ankit Mangla from University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, and Case Comprehensive Cancer Center discuss angiosarcomas—mesenchymal tumors that arise from the endothelium of blood or lymphatic vessels. Primary hepatic angiosarcoma (PHA) is the most common mesenchymal tumor of the liver, yet very rare.

"In our analysis of the National Cancer Database (2004–2014), the incidence of PHA was only 0.29% compared to hepatocellular carcinoma (HCC), which is the most common epithelial tumor of the liver," said the researchers.

The editorial paper was published in Oncoscience on May 20, 2024, titled "Primary hepatic angiosarcoma: Treatment options for a rare tumor."

A high index of suspicion is needed to diagnose PHA. The clinical presentation of PHA is very similar to that of (HCC). In a patient with presenting with a liver mass, typical imaging findings are usually sufficient to diagnose HCC.

Where a is seldom performed to establish the diagnosis of HCC, the diagnosis of PHA is exclusively based on pathologic confirmation. The prognosis of patients with PHA is much worse compared to those with HCC (1.9 versus 10.3 months, adjusted hazard ratio (aHR) 2.41, 95% Confidence Interval (CI): 2.1–2.77, p
"Hence, diagnosing PHA at the outset is critical to determine prognosis and direct the correct treatment," they added.

More information: Gregory L. Guzik et al, Primary hepatic angiosarcoma: Treatment options for a rare tumor, Oncoscience (2024). DOI: 10.18632/oncoscience.602

Provided by Impact Journals LLC
Citation: Primary hepatic angiosarcoma: Treatment options for a rare tumor (2024, June 21) retrieved 24 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

New thesis on biomarkers for hepatocellular carcinoma


Feedback to editors